NTRK1 and neoplasm: Sorafenib inhibits angiogenesis and tumour progression by limiting the effects of various receptor tyrosine kinases such as VEGFR-2, VEGFR-3, c-KIT, or platelet-derived growth factor receptor beta (PDGFRβ) [14].